Phase I Trial of CAR T Cells with Chlorotoxin for MMP2+ Recurrent Glioblastoma
A phase I trial is underway to evaluate CAR T cells targeting MMP2+ glioblastoma, focusing on safety and dosing.
Therapeutic Area
Therapeutic area intelligence for CAR T-cell Therapy with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.